Skip to main content

Table 1 Summary of neoepitope landscape in the PCGP cohort

From: The neoepitope landscape in pediatric cancers

Project

Class

Disease

Patient number

Sample numbera

Average number of mutationsb

Average number of neoepitope (≤500 nM)b

Average number of expressed neoepitopesb

PCGP

LEUKEMIA

ETV

49

56 (7)

11.22 (20.73)

4.29 (9.25)

1.68 (4.09)

HYPER

53

53

9.49

4.11

-

BALL

31

31

11.58

5.03

2.00

HYPO

22

22

9.64

3.23

1.50

TALL

10

10

8.10

3.60

-

ERG

25

25

8.40

3.16

1.28

CBF

16

16

6.38

2.13

0.89

INF

19

21(2)

2.47 (3.57)

1.11 (1.52)

0.44 (0.44)

PHALL

35

35

4.49

1.83

0.52

E2A

21

21

5.48

2.10

-

AMLM7

3

3

2.67

0.67

0.33

Subtotal

284

293

   

CNS

HGG

32

35 (3)

17.97 (17.46)

8.59 (8.20)

3.68 (3.56)

EPD

32

34 (2)

5.06 (5.68)

1.78 (1.91)

0.93 (0.96)

MB

34

34

8.94

3.68

4.25

LGG

23

23

1.74

0.65

0.33

CPC

2

2

2.00

1.50

-

Subtotal

123

128

   

SOLID

MEL

4

4

112.25

51.25

6.00

NBL

44

47 (3)

15.2 (16.62)

7.09 (7.79)

-

ACT

20

20

11.75

3.70

1.75

RHB

14

15 (1)

15.14 (18.00)

6.71 (8.13)

2.08 (3.14)

OS

27

27

18.22

7.07

2.92

RB

5

5

5.20

2.40

-

EWS

19

19

5.63

2.00

-

Subtotal

133

137

   

TCGA

 

LUAD

129

129

226.63

95.74

36.99

LUSC

33

33

224.58

95.88

58.06

SKCM

133

133

411.50

167.57

60.64

Subtotal

295

295

   
  1. aThe number in the parentheses denotes the number of relapse samples
  2. bThe number in the parentheses denotes the average number when relapse samples included